Healthcare Global Enterprises Ltd Q1 FY26 – Cancer Hospitals at 246x PE, 88% Promoter Pledge, and a ₹9,128 Cr Valuation Circus 🎪
1. At a Glance
Healthcare Global Enterprises Ltd (NSE: HCG, CMP ₹647, Market Cap ₹9,128 Cr) is the desi king of cancer care, fertility treatments, and — unintentionally — investor headaches. In the last one year, the stock delivered a 51% return, which makes you wonder: is it the hospital business or the PE ratio-induced fever that’s spreading? With sales of ₹2,310 Cr, PAT of barely ₹37 Cr, and a stock P/E of 246, this is the financial equivalent of paying ₹500 for a hospital vada pav. Add 88% promoter pledge, 2% net margins, and debt of ₹1,837 Cr, and you have a company where the doctors save lives but investors lose hair.
2. Introduction
Welcome to the rollercoaster called HCG — India’s largest private cancer hospital chain (by licenses, not by profits). They run 22 comprehensive cancer centers, 4 multi-specialty hospitals, and 7 fertility centers under “Milann.” In total: ~1,944 beds, which means if Netflix ever does “Cancer Care Wars,” HCG gets top billing.
The business model is noble (saving lives), the revenue is growing at 17% CAGR, but the profits look like your weight-loss chart — promising in theory, disappointing in reality. Occupancy is 64% (good), ARPOB is ₹42,000 (premium), but ROE is only 5% (bad).
And the drama? Oh, plenty. In 2025, Hector Asia Holdings swooped in, acquired 51%, replaced the CEO, shuffled the board, and launched a takeover worthy of a Bollywood family feud. The cherry on top: CFO resigned last month. Investors are now wondering if this is a hospital or a daily soap set in scrubs.
So, is HCG the next Apollo Hospitals in the making, or just another Fortis circa 2017 (remember Singh brothers’ pledge mess)? Let’s dissect like a sarcastic surgeon.
3. Business Model – WTF Do They Even Do?
Two main verticals:
Cancer Care (HCG brand): 22 centers across India + 1 in Kenya. They treat patients with OPD consultations, chemo sessions (41% of revenue), radiotherapy using LINAC machines (17%), and inpatient services (24%). Basically, they bill you whether you walk in, lie down, or get zapped by radiation.
Fertility (Milann brand): 5 centers in Bengaluru + a few trimmed in Delhi. IVF cycles = ~1,100 in H1 FY24. Profitability? More like your neighbor’s startup — emotionally strong, financially weak.
Revenue Mix H1 FY24: OPD 18%, Chemo 41%, LINAC 17%, Inpatient 24%. Translation: chemotherapy is the cash cow.
Question: Would you pay 246x earnings for a company whose main “profit driver” is chemotherapy? Investors apparently do.
